Key regions: Australia, Japan, United States, Germany, Europe
Despite the small size of the country, Haiti's pharmaceutical market has been growing rapidly in recent years. One of the areas that have seen significant development is the Anti-Coagulants market.
Customer preferences: There is a growing demand for Anti-Coagulants in Haiti due to the increasing prevalence of cardiovascular diseases and strokes. Patients are seeking effective and safe treatments to manage their conditions, and Anti-Coagulants have been proven to be a reliable option. Additionally, as the population ages, the demand for Anti-Coagulants is expected to rise further.
Trends in the market: One of the major trends in the Anti-Coagulants market in Haiti is the shift towards newer oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, apixaban, and edoxaban. These drugs are more convenient to use than traditional warfarin, do not require regular monitoring, and have fewer drug interactions. As a result, they have become increasingly popular among patients and healthcare providers. Moreover, the government has been promoting the use of generic NOACs, which has led to increased competition and lower prices.
Local special circumstances: Haiti is a low-income country with a high burden of disease, and access to healthcare is limited. The government has been working to improve the healthcare system by investing in infrastructure, training healthcare workers, and increasing access to essential medicines. However, there are still significant challenges, including a shortage of healthcare professionals, inadequate funding, and poor distribution systems. These factors can affect the availability and affordability of Anti-Coagulants and other essential medicines.
Underlying macroeconomic factors: Haiti's economy is heavily dependent on agriculture and remittances, and the country has been struggling with political instability, social unrest, and natural disasters. These factors can affect the availability and affordability of medicines, including Anti-Coagulants. Additionally, the COVID-19 pandemic has had a significant impact on the healthcare system, disrupting supply chains and increasing demand for essential medicines. Despite these challenges, the Anti-Coagulants market in Haiti is expected to continue growing, driven by the increasing prevalence of cardiovascular diseases and strokes, as well as the government's efforts to improve healthcare access and affordability.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
